Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Evaluation of Clinical Significance of Kallistatin and Macrophage Inflammatory Protein-1B for the Diagnosis of Liver Cirrhosis and Hepatocellular Carcinoma in Egyptian Patients


Affiliations
1 Biochemistry Division, Chemistry Department, Zagazig University, Egypt
2 Medical Analysis Specialist, Zagazig University, 01224112677, Egypt
     

   Subscribe/Renew Journal


Background: Early diagnosis of liver diseases especially hepatocellular carcinoma is very important. Cirrhosis is diagnosed clinically by using of laboratory analysis and imaging data, and liver biopsy. However, these methods have their limitations. These findings suggest the need for diagnostic biomarkers that could add to the sensitivity and accuracy. Serum Kallistatin may fall into this category of biomarkers as the liver represents the major site of synthesis and secretion of it and their levels reflect the synthetic function of liver. Objective: To assess serum Kallistatin and CCL4 levels in cases of liver cirrhosis due to any factor and hepatocellular carcinoma. Methods: Sixty patients who were included and classified into 30 patients with liver cirrhosis, 40 patients with hepatocellular carcinoma. They were compared with 20 sex and age matched healthy individuals for control. Levels of serum kallistatin was measured by enzyme-linked immunosorbent assay and serum cholinesterase was measured using colorimetric assay. Results: There was a highly significant decrease in serum Kallistatin and high significant increase of CCL4 in patients with liver cirrhosis when compared with control (P<0.000). However, there was a slight but not significant increase in kallistatin level in HCC group compared with control and significant increase in CCL4 level in HCC group compared with control. Conclusion: Both serum kallistatin and CCL4 can be used as reliable biomarkers for the diagnosis of, evaluation of the extent of liver cirrhosis and hepatocellular carcinoma.

Keywords

Kallistatin, CCL4, Liver Cirrhosis, Hepatocellular Carcinoma.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World journal of hepatology. 2015 Feb 27;7(2):139.

  • Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. European journal of radiology. 2018 Apr 1;101:72-81.

  • Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World journal of gastroenterology: WJG. 2015 Oct 7;21(37):10573.

  • Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015 Oct 1;149(5):1226-39.

  • Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma (Review). Molecular and clinical oncology. 2013 Jul 1;1(4):593-8.

  • Lien MY, Tsai HC, Chang AC, Tsai MH, Hua CH, Wang SW, Tang CH. Chemokine CCL4 Induces Vascular Endothelial Growth Factor C Expression and Lymphangiogenesis by miR195-3p in Oral Squamous Cell Carcinoma. Frontiers in immunology. 2018 Mar 2;9:412.

  • M Sadeghi, I Lahdou, H Oweira, V Daniel, P Terness, J Schmidt, K-H Weiss, T Longerich,PSchemmer, G Opelz and A Mehrabi (2015): Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. British Journal of Cancer. 113: 756–762.

  • Cao Z, Fu B, Deng B, Zeng Y, Wan X, Qu L. Overexpression of Chemokine (CXC) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma. Cancer cell international. 2014 Dec;14(1):86.

  • Hefetz-Sela S, Stein I, Klieger Y, Porat R, Sade-Feldman M, Zreik F, Nagler A, Pappo O, Quagliata L, Dazert E, Eferl R. Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proceedings of the National Academy of Sciences. 2014 Dec 9;111(49):17582-7.

  • Chao J, Li P, Chao L. Kallistatin suppresses cancer development by multi-factorial actions. Critical reviews in oncology/hematology. 2017 May 1;113:71-8.

  • Härdle W and Simar L (2007). Applied Multivariate Statistical Analysis. 2nd ed, Springer, 420pp.

  • Freeman RB, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997–2006. American Journal of Transplantation. 2008 Apr 1;8(4p2):958-76.

  • Serpaggi J, Carnot F, Nalpas B, Canioni D, Guéchot J, Lebray P, Vallet-Pichard A, Fontaine H, Bedossa P, Pol S. Direct and indirect evidence for the reversibility of cirrhosis. Human pathology. 2006 Dec 31;37(12):1519-26.

  • Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Annals of Internal Medicine. 2000 Apr 4;132(7):517-24.

  • Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004 Jun 1;39(6):1647-54.

  • Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clinics in liver disease. 2005 Feb 28;9(1):135-49.

  • Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 2002 May 31;122(5):1525-8.

  • Xu R, Harrison PM, Chen M, Li L, Tsui TY, Fung PC, Cheung PT, Wang G, Li H, Diao Y, Krissansen GW. Cytoglobin overexpression protects against damage-induced fibrosis. Molecular Therapy. 2006 Jun 30;13(6):1093-100.

  • Chao J, Miao RQ, Chen V, Chen LM, Chao L. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biological chemistry. 2001 Jan 6;382(1):15-21.

  • Zhou GX, Chao L, Chao J. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. Journal of Biological Chemistry. 1992 Dec 25;267(36):25873-80.

  • Wang MY, Day J, Chao L, Chao J. Human kallistatin, a new tissue kallikrein-binding protein: purification and characterization. Advances in experimental medicine and biology. 1989;247:1-8.

  • Chao J, Schmaier A, Chen LM, Yang Z, Chao L. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. Journal of Laboratory and Clinical Medicine. 1996 Jun 30;127(6):612-20.

  • Chai KX, Chen LM, Chao J, Chao L. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. Journal of Biological Chemistry. 1993 Nov 15;268(32):24498-505.

  • Chao J, Chao L. Biochemistry, regulation and potential function of kallistatin. Biological chemistry Hoppe-Seyler. 1995 Dec;376(12):705-13.

  • Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S, Xu T, Spalding D, Habib N, Xu R. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. ActaPharmaceuticaSinica B. 2015 May 31;5(3):194-200.

  • Shen B, Chao L, Chao J. Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. American Journal of Physiology-Heart and Circulatory Physiology. 2010 Mar 1;298(3):H1048-54.

  • Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002 Nov 1;100(9):3245-52.

  • Thongboonkerd V, Gozal E, Sachleben LR, Arthur JM, Pierce WM, Cai J, Chao J, Bader M, Pesquero JB, Gozal D, Klein JB. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. Journal of Biological Chemistry. 2002 Sep 20;277(38):34708-16.

  • Shen B, Hagiwara M, Yao YY, Chao L, Chao J. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008 May 1;51(5):1358-65.

  • Amany M. Elsaeed1,*, Sahar Mohamed Ismail2, Naglaa A. Elgendy3. Serum Kallistatin and Cholinesterase as Biomarkers for the Diagnosis of Liver Cirrhosis in Patients with Hepatitis C Viral Infection. Clinical Medicine and Diagnostics 2016, 6(6): 143-152

  • Maghazachi AA. Role of chemokines in the biology of natural killer cells. InThe Chemokine System in Experimental and Clinical Hematology 2010 (pp. 37-58). Springer Berlin Heidelberg.

  • Ingelsten M, Karlsson-Parra A, Granqvist AB, Mölne J, Olausson M, Haraldsson B, Nyström J. Postischemic inflammatory response in an auxiliary liver graft predicts renal graft outcome in sensitized patients. Transplantation. 2011 Apr 27;91(8):888-94.

  • Bautista AP. Acute alcohol intoxication and endotoxemia desensitize HIV-1 gp120-induced CC-chemokine production by Kupffer cells. Life sciences. 2001 Mar 16;68(17):1939-49.

  • Bautista AP, Wang E. Chronic ethanol intoxication enhances the production of cytokine-induced neutrophil chemoattractant and macrophage inflammatory protein-2 by hepatocytes after human immunodeficiency virus-1 glycoprotein 120 vaccination. Alcohol. 2001 May 31;24(1):35-44.

  • Kang W, Shin EC. Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Yonsei medical journal. 2011 Nov 1;52(6):871-8.

  • Larrubia JR, Benito-Martínez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol. 2008 Dec 21;14(47):7149-59.

  • Moura AS, Carmo RA, Teixeira AL, Rocha MO. Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C. Brazilian Journal of Infectious Diseases. 2009 Oct;13(5):375-82.

  • Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Opelz G, Mehrabi A. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. British journal of cancer. 2015 Sep;113(5):756.


Abstract Views: 233

PDF Views: 0




  • Evaluation of Clinical Significance of Kallistatin and Macrophage Inflammatory Protein-1B for the Diagnosis of Liver Cirrhosis and Hepatocellular Carcinoma in Egyptian Patients

Abstract Views: 233  |  PDF Views: 0

Authors

Al-Shimaa M. Abas
Biochemistry Division, Chemistry Department, Zagazig University, Egypt
Moustafa Salaheldein Abdelhamid
Biochemistry Division, Chemistry Department, Zagazig University, Egypt
Noha Mohamed said
Biochemistry Division, Chemistry Department, Zagazig University, Egypt
Marwa Sayed Sabea
Medical Analysis Specialist, Zagazig University, 01224112677, Egypt

Abstract


Background: Early diagnosis of liver diseases especially hepatocellular carcinoma is very important. Cirrhosis is diagnosed clinically by using of laboratory analysis and imaging data, and liver biopsy. However, these methods have their limitations. These findings suggest the need for diagnostic biomarkers that could add to the sensitivity and accuracy. Serum Kallistatin may fall into this category of biomarkers as the liver represents the major site of synthesis and secretion of it and their levels reflect the synthetic function of liver. Objective: To assess serum Kallistatin and CCL4 levels in cases of liver cirrhosis due to any factor and hepatocellular carcinoma. Methods: Sixty patients who were included and classified into 30 patients with liver cirrhosis, 40 patients with hepatocellular carcinoma. They were compared with 20 sex and age matched healthy individuals for control. Levels of serum kallistatin was measured by enzyme-linked immunosorbent assay and serum cholinesterase was measured using colorimetric assay. Results: There was a highly significant decrease in serum Kallistatin and high significant increase of CCL4 in patients with liver cirrhosis when compared with control (P<0.000). However, there was a slight but not significant increase in kallistatin level in HCC group compared with control and significant increase in CCL4 level in HCC group compared with control. Conclusion: Both serum kallistatin and CCL4 can be used as reliable biomarkers for the diagnosis of, evaluation of the extent of liver cirrhosis and hepatocellular carcinoma.

Keywords


Kallistatin, CCL4, Liver Cirrhosis, Hepatocellular Carcinoma.

References